Literature DB >> 29556602

Tau protein in neurodegenerative diseases - a review.

Denisa Floriana Vasilica Pîrşcoveanu1, Ionica Pirici, Valerica Tudorică, Tudor Adrian Bălşeanu, Valeria Carmen Albu, Simona Bondari, Ana Maria Bumbea, Mircea Pîrşcoveanu.   

Abstract

The study of rare, inherited forms of different diseases resulted in the discovery of gene defects that cause inherited variants of the respective diseases. The defective genes were found to encode major molecular players leading to the neuropathological lesions or factors that characterize these diseases. The exact role of the tau protein in the neurodegenerative process is still under debate. It is very important to understand the normal biological roles of tau and the specific events that induce tau to become neurotoxic. Tau is the major microtubule-associated protein (MAP) of a mature neuron. The other neuronal MAPs are MAP1 and MAP2. These three MAPs perform similar function, promoting assembly and stability of microtubules. Tau protein was isolated as a microtubule-associated factor in the porcine brain. It was isolated as a protein that co-purified with tubulin and had the ability to promote microtubule assembly in vitro. Normal adult human brain tau contains 2-3 moles phosphate÷mole of tau protein. Hyperphosphorylation of tau depress this biological activity of tau. Almost 80 diseases caused by missense mutations and intronic mutations in the tau gene have been found in familial cases of frontotemporal dementia (FTD). In Alzheimer's disease (AD), there are intraneuronal neurofibrillary tangles composed of the microtubule-associated protein tau (MAPT). In other neurodegenerative diseases, there are similar deposits of tau, in the absence of extracellular deposits (progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, etc.). Tau pathology is also often seen in some forms of Parkinson's disease (PD) and prion diseases. In genetic forms of FTD, mutations in tau implicate abnormal tau as the initiation of neurodegeneration. In FTD, there are deposits especially in temporal and frontal lobes, regions that are very important for behavior and executive function. It is critical to understand how tau becomes pathogenic, in order to consider developing any strategies for treatment.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29556602

Source DB:  PubMed          Journal:  Rom J Morphol Embryol        ISSN: 1220-0522            Impact factor:   1.033


  17 in total

Review 1.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

Review 2.  Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Authors:  Dharmendra Kumar Khatri; Amey Kadbhane; Monica Patel; Shweta Nene; Srividya Atmakuri; Saurabh Srivastava; Shashi Bala Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-04-08

3.  Glucose Starvation Causes ptauS409 Increase in N2a Cells Through ATF3/PKAcα Signaling Pathway.

Authors:  Zifan Zuo; Ling Li; Xuli Yan; Lianwen Zhang
Journal:  Neurochem Res       Date:  2022-07-20       Impact factor: 4.414

Review 4.  Waste Clearance in the Brain.

Authors:  Jasleen Kaur; Lara M Fahmy; Esmaeil Davoodi-Bojd; Li Zhang; Guangliang Ding; Jiani Hu; Zhenggang Zhang; Michael Chopp; Quan Jiang
Journal:  Front Neuroanat       Date:  2021-07-07       Impact factor: 3.856

5.  Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau.

Authors:  Hyeanjeong Jeong; Seulgi Shin; Jun-Seok Lee; Soo Hyun Lee; Ja-Hyun Baik; Sungsu Lim; Yun Kyung Kim
Journal:  Int J Mol Sci       Date:  2019-09-01       Impact factor: 5.923

6.  Selenization of S. cerevisiae increases its protective potential in experimental autoimmune encephalomyelitis by triggering an intestinal immunomodulatory loop.

Authors:  Thais Fernanda de Campos Fraga-Silva; Luiza Ayumi Nishiyama Mimura; Larissa Ragozo Cardoso de Oliveira; Juliana Helena Dos Santos Toledo; Patrícia Aparecida Borim; Sofia Fernanda Gonçalvez Zorzella-Pezavento; Diego Peres Alonso; Paulo Eduardo Martins Ribolla; Carlos Alberto Ferreira de Oliveira; Denise Morais da Fonseca; Eduardo J Villablanca; Alexandrina Sartori
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

Review 7.  Inhibition of Astrocytic Histamine N-Methyltransferase as a Possible Target for the Treatment of Alzheimer's Disease.

Authors:  Cecilia Flores-Clemente; María Inés Nicolás-Vázquez; Elvia Mera Jiménez; Maricarmen Hernández-Rodríguez
Journal:  Biomolecules       Date:  2021-09-26

8.  Comparative Analysis of Multiple Neurodegenerative Diseases Based on Advanced Epigenetic Aging Brain.

Authors:  Feitong Shi; Yudan He; Yao Chen; Xinman Yin; Xianzheng Sha; Yin Wang
Journal:  Front Genet       Date:  2021-05-20       Impact factor: 4.599

9.  Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction.

Authors:  Lubov A Ezerskiy; Kathleen M Schoch; Chihiro Sato; Mariana Beltcheva; Kanta Horie; Frank Rigo; Ryan Martynowicz; Celeste M Karch; Randall J Bateman; Timothy M Miller
Journal:  JCI Insight       Date:  2022-01-11

10.  A Longitudinal, Observational Analysis of Neuronal Injury Biomarkers in a Case Report of a Patient With Paraneoplastic Anti-CRMP5 Antibody-Associated Transverse Myelitis.

Authors:  Christopher Mizenko; Jeffrey L Bennett; Gregory Owens; Timothy L Vollmer; Amanda L Piquet
Journal:  Front Neurol       Date:  2021-07-16       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.